EyePoint Pharmaceuticals, Inc.
EYPTNext catalyst
EYP-1901
Diabetic Macular Edema
Get an email about EYPT's next catalysts
Track EyePoint Pharmaceuticals (EYPT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 2 past
EYP-1901 Phase 3 Est. Readout (DME)
Estimated primary completion for EYP-1901 trial (NCT07449936) in Diabetic Macular Edema. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
EyePoint Pharmaceuticals Inc. (formerly pSivida Corporation) is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery.
WebsiteFAI insert
Non-Infectious Uveitis
FAI Insert administered using the Mk II inserter
Non-Infectious Uveitis
EYP-1901
Diabetic Macular Edema
Latanoprost ophthalmic solution
Ocular Hypertension
AKB-9778
Nonproliferative Diabetic Retinopathy
Aflibercept/Inj,Oph
Wet Age-related Macular Degeneration
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FAI insert | Phase 3 | Non-Infectious Uveitis | - | - |
FAI Insert administered using the Mk II inserter | Phase 3 | Non-Infectious Uveitis | - | - |
EYP-1901 | Phase 3 | Diabetic Macular Edema | - | - |
Latanoprost ophthalmic solution | Phase 2 | Ocular Hypertension | - | - |
AKB-9778 | Phase 2 | Nonproliferative Diabetic Retinopathy | - | - |
Aflibercept/Inj,Oph | Phase 2 | Wet Age-related Macular Degeneration | - | - |
Frequently asked questions
What is in EyePoint Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in EyePoint Pharmaceuticals, Inc.'s (EYPT) pipeline across Phase 3, Phase 2. Its lead program is EYP-1901 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is EyePoint Pharmaceuticals, Inc.'s next FDA catalyst?→
EyePoint Pharmaceuticals, Inc.'s (EYPT) next tracked catalyst is a Phase 3 readout expected October 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track EYPT biotech catalysts?→
Add EYPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow EyePoint Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.